Imaging of matrix metalloproteinase inhibitors
AssigneesMicro Vide, LLC, Yale University
InventorsAlbert J. Sinusas, Francis G. Spinale, Paul Heerdt, Stephanie Thorn
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed in part to methods of imaging a subject's lung, including but not limited to the purpose of evaluating a pulmonary infection in a subject. The method includes administering an imaging agent comprising a 99mTc-labeled matrix metalloproteinase targeted radiotracer to a subject, acquiring an image of the subject's lung using SPECT/CT imaging, and measuring an amount of the imaging agent bound to matrix metalloproteinase in the subject's lung (or localized to the lung). Additionally, the present disclosure is directed in part to a method of high resolution imaging of a subject's heart tissue.
Claims38
A method of imaging a subject's lung, the method comprising:
- administering to the subject's lung an imaging agent comprising a 99mTc-labeled matrix metalloproteinase targeted radiotracer;
- acquiring an image of the subject's lung using single-photon emission computed tomography/computed tomographic (SPECT/CT) imaging, optionally using dynamic imaging;
- and
- measuring an amount of the imaging agent bound to matrix metalloproteinase in the subject's lung.
A method of evaluating a pulmonary infection in a subject, the method comprising:
- administering an imaging agent comprising a 99mTc-labeled matrix metalloproteinase targeted radiotracer to a subject's lung;
- acquiring an image of the subject's lung using single-photon emission computed tomography/computed tomographic (SPECT/CT) imaging, optionally using dynamic imaging;
- and
- measuring an amount of the imaging agent bound to matrix metalloproteinase in the subject's lung,
- wherein the presence of the imaging agent bound to a matrix metalloproteinase in an amount higher than an amount in a reference subject indicates the subject is afflicted with a pulmonary infection.
A method of high resolution imaging of a subject's heart tissue, the method comprising:
- administering to the subject's heart tissue a first imaging agent comprising a 99mTc-labeled matrix metalloproteinase targeted radiotracer;
- acquiring an image of the subject's heart tissue using single-photon emission computed tomography/computed tomographic (SPECT/CT) imaging, optionally using dynamic imaging;
- and
- quantifying an amount of the first imaging agent bound to a matrix metalloproteinase in the subject's heart tissue.
Dependencies are inferred from the claim text.